RxDoctor Payments Data

Heather Holfinger

Family · Fort Myers, FLNPI 1902238801

Payments from drug & device makers

$4,154in general payments, 2019–2025

Across 64 payments — averaging $64.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$854
  • Boston Scientific$147
  • Madrigal Pharmaceuticals$141
  • Daiichi Sankyo Inc.$138
  • Ipsen Biopharmaceuticals, Inc$128
  • plus $713 from 11 others

What the payments were for

  • Food & beverage$4,10299%
  • Education$521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,154 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$59,687
Medicare patients
357
Services billed
529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$90,454
XifaxanRifaximin14$48,114
LinzessLinaclotide29$16,801
SutabSod Sulf/Pot Chloride/Mag Sulf31$5,038
Ursodiol12$4,628
Dexlansoprazole DrDexlansoprazole17$4,113
Pantoprazole Sodium339$4,107
Omeprazole256$3,320
Famotidine151$1,266
Colestipol Hcl20$1,043
Lubiprostone11$743
Esomeprazole Magnesium31$656
Sulfasalazine11$503
Hydrocortisone30$492
Dicyclomine Hcl25$458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$65$48,11414 claims
AbbVieLinzess$2,032$16,80129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.

Other family in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →